The label-free Raman imaging of human breast cancer

2011 ◽  
Vol 164 (1-2) ◽  
pp. 123-131 ◽  
Author(s):  
Halina Abramczyk ◽  
Beata Brozek-Pluska ◽  
Jakub Surmacki ◽  
Joanna Jablonska ◽  
Radzislaw Kordek
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Raman Imaging ◽  
Label Free ◽  
Human Breast

scholarly journals Advancing the Role of Gamma-Tocotrienol as Proteasomes Inhibitor: A Quantitative Proteomic Analysis of MDA-MB-231 Human Breast Cancer Cells

Biomolecules ◽  
2019 ◽  
Vol 10 (1) ◽  
pp. 19
Author(s):  
Premdass Ramdas ◽  
Ammu Kutty Radhakrishnan ◽  
Asmahani Azira Abdu Sani ◽  
Mangala Kumari ◽  
Jeya Seela Anandha Rao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
In Vivo Studies ◽  
Nuclear Fraction ◽  
Label Free ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Gamma Tocotrienol

Tocotrienol, an analogue of vitamin E has been known for its numerous health benefits and anti-cancer effects. Of the four isoforms of tocotrienols, gamma-tocotrienol (γT3) has been frequently reported for their superior anti-tumorigenic activity in both in vitro and in vivo studies, when compared to its counterparts. In this study, the effect of γT3 treatment in the cytoplasmic and nuclear fraction of MDA-MB-231 human breast cancer cells were assessed using the label-free quantitative proteomics analysis. The cytoplasmic proteome results revealed the ability of γT3 to inhibit a group of proteasome proteins such as PSMA, PSMB, PSMD, and PSME. The inhibition of proteasome proteins is known to induce apoptosis in cancer cells. As such, the findings from this study suggest γT3 as a potential proteasome inhibitor that can overcome deficiencies in growth-inhibitory or pro-apoptotic molecules in breast cancer cells. The nuclear proteome results revealed the involvement of important nuclear protein complexes which hardwire the anti-tumorigenesis mechanism in breast cancer following γT3 treatment. In conclusion, this study uncovered the advancing roles of γT3 as potential proteasomes inhibitor that can be used for the treatment of breast cancer.

scholarly journals Fast label-free multilayered histology-like imaging of human breast cancer by photoacoustic microscopy

2017 ◽  
Vol 3 (5) ◽  
pp. e1602168 ◽  
Author(s):  
Terence T. W. Wong ◽  
Ruiying Zhang ◽  
Pengfei Hai ◽  
Chi Zhang ◽  
Miguel A. Pleitez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Photoacoustic Microscopy ◽  
Label Free ◽  
Human Breast

scholarly journals Label-free, microfluidic separation and enrichment of human breast cancer cells by adhesion difference

Lab on a Chip ◽  
2007 ◽  
Vol 7 (11) ◽  
pp. 1461 ◽  
Author(s):  
Keon Woo Kwon ◽  
Sung Sik Choi ◽  
Sang Ho Lee ◽  
Byungkyu Kim ◽  
Se Na Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Label Free ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Microfluidic Separation

scholarly journals Investigating the effects of Pentoxifylline on human breast cancer cells using Raman spectroscopy

2015 ◽  
Vol 08 (02) ◽  
pp. 1550004 ◽  
Author(s):  
Peeyush N. Goel ◽  
S. P. Singh ◽  
C. Murali Krishna ◽  
R. P. Gude
Keyword(s):  
Breast Cancer ◽  
Raman Spectroscopy ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Label Free ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Drug Induced ◽  
Linear Discriminant

Breast cancer is one of the leading causes of cancer-related deaths in a global scenario. In the present study, biochemical changes exerted upon Pentoxifylline (PTX) treatment had been appraised in human breast cancer cells using Raman spectroscopy. There are no clinically approved methods to monitor such therapeutic responses available. The spectral profiling is suggestive of changes in DNA, protein and lipid contents showing a linear relationship with drug dosage. Further, multivariate analysis using principal-component based linear-discriminant-analysis (PC-LDA) was employed for classifying the control and the PTX treated groups. These findings support the feasibility of Raman spectroscopy as an alternate/adjunct label-free, objective method for monitoring drug-induced modifications against breast cancer cells.

Sign in / Sign up

Export Citation Format

Share Document